Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Larysa Mykhailova has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cord Blood-Derived Versus Homologous Donor Platelet-Rich Plasma (PRP) in Early Knee Osteoarthritis: A Single-Center, Randomized, Double-Blind Pilot Clinical Trial

    by Salvatore Alessio Angileri, Enrica Cristini, Simone Mazzola, Giovanni Maria Rodà, Chloe Yeabin Jung, Salvatore Valentino, Stefania Villa, Tiziana Montemurro, Larysa Mykhailova, Letizia Di Meglio, et al.

    Intra-articular platelet-rich plasma (PRP) injections represent a promising biological treatment for early-stage knee osteoarthritis (KOA). As cord blood-derived PRP (CB-PRP) contains higher levels of bioactive mediators, this prospective study aimed to compare the efficacy and safety of CB-PRP versus homologous donor PRP (HD-PRP) in patients with early KOA and to evaluate whether CB-PRP results in greater clinical improvement. Fifty-one patients aged 46–70 years with Kellgren–Lawrence grade 1–2 were randomized to receive either CB-PRP or HD-PRP. Each underwent three intra-articular injections at four-week intervals. Outcomes included pain-related overall health perception assessed by the EuroQol Visual Analogue Scale (EQ-VAS), function measured with the Knee Injury and Osteoarthritis Outcome Score (KOOS), and quadriceps muscle strength evaluated by dynamometry. Assessments were performed at baseline and at 1, 2, 3, 6, and 12 months. Both groups showed improvements in pain and function over 12 months, with no statistically significant between-group differences (p = 0.46). EQ-VAS increased from 59 ± 19 to 83 ± 9 in the CB-PRP group and from 59 ± 18 to 77 ± 18 in the HD-PRP group. KOOS improved from 50 ± 25 to 68 ± 23 and from 38 ± 28 to 59 ± 24, respectively. Quadriceps strength showed no intergroup differences. Adverse events were mild and self-limiting. Both treatments demonstrated comparable clinical benefits and favorable safety profiles.

  • Open Access

    Rheological and biochemical comparison of cord and adult blood red cells for transfusion applications

    by Larysa Mykhailova, Cristina Vercellati, Tiziana Montemurro, Anna Zaninoni, Anna Marcello, Elisa Fermo, Alessandro Cherubini, Silvia Cimoni, Paola Bianchi, Daniele Prati, et al.

    Cord blood (CB) is a promising alternative source of red blood cells (CB-RBC) for neonatal transfusion due to their high fetal hemoglobin content and potential physiological benefits in preterm infants, but their metabolic and rheological stability during storage and irradiation is not fully defined. This study examined whole cord blood (WCB) and processed CB-RBC stored up to 10 days (D10), with or without irradiation, and compared them with adult RBC (A-RBC) following neonatal transfusion guidelines. Ektacytometry showed significantly lower EImax in CB-RBC at day 0 (D0) and D10 ( p < 0.05), while Omin and Ohyper remained stable. CB-RBC had lower ATP than A-RBC at baseline (2.8 ± 1.0 µmol/g Hb vs. 4.0 ± 0.3 µmol/g Hb) and after 10 days (2.0 ± 1.1 µmol/g Hb vs. 3.0 ± 1.9 µmol/g Hb). Hemolysis in CB-RBC was minimal (median 0.05, range 0.04–1.17% at D0 vs. median 0.19, range 0.16–1.23% at D10), and residual WBC content met limits (< 1 × 10⁶). Storage induced expected biochemical changes in both CB-RBC and A-RBC, including increased potassium, pO2 and lactate, decreased sodium and glucose, and pH decline, though D10 pH and potassium evaluation in CB-RBC was partly affected by hemolysis. Irradiation produced minimal effects on ATP and rheology. Overall, CB-RBC preserved acceptable metabolic and rheological properties during short-term storage and irradiation, supporting further exploration of their suitability for neonatal transfusion.


  • Open Access

    Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise

    by Larysa Mykhailova, Paolo Rebulla, Stefania Villa, Erica Scalambrino, Marigrazia Clerici, Armando Tripodi, Evelyn Ferri, Beatrice Arosio, Alessandro Cherubini, Dinara Samarkanova, et al.

    Background: Characterization of platelet gel (PG) from different blood sources and preparation methods remains incomplete. Study Design and Methods: This study compared the weight, growth factor (GF) content, and gelation dynamics (via rotational thromboelastometry, ROTEM) of allogeneic PG prepared from adult blood (AB) and cord blood (CB) platelet concentrates (PC). ABPC were suspended in 100% plasma or 35% plasma/65% platelet additive solution (PAS), while CBPC were suspended in 100% plasma. PG was prepared in commercial BioNest D mini‐bags using a method with calcium gluconate, locally made cryoprecipitate, and thrombin (CT), or a reference method with calcium gluconate and commercial batroxobin (BA). PG was analyzed at 30 min and 6 h. Results: At 30 min, PG weights were higher with CT than BA across all conditions. With 5 mL ABPC in 100% plasma, weights were 7.20 ± 1.07 g (CT) versus 2.72 ± 0.19 g (BA); with 10 mL ABPC in PAS, 9.49 ± 2.86 g (CT) versus 3.87 ± 3.1 g (BA); and with 4.09 ± 0.45 mL CBPC, 5.62 ± 1.21 g (CT) versus 2.04 ± 0.78 g (BA). All PGs lost mass by 6 h, but CT consistently retained more weight. GF percent retention in the PG at 6 h was higher with CT. ROTEM results showed differences in clotting time and comparable values of maximum clot firmness between PG from AB and CB. Discussion: The CT method is a promising alternative for producing allogeneic PG using affordable, locally sourced reagents.


  • Open Access

    A procedure using low‐cost reagents to prepare allogeneic platelet gel from standard platelet units

    by Larysa Mykhailova, Javier Calvo, Anthi Gafou, Josè Antonio Garcìa Erce, Evangelia Lydaki, Maria Elena Schinocca, Dinara Samarkanova, Gabriele Scimemi, Tiziana Montemurro

    Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.

  • Open Access

    First use of cord blood platelet-rich plasma in the treatment of vulvar lichen sclerosus: a preliminary study towards a randomized controlled trial.

    by Veronica Boero, Carlotta Caia, Giulia E Cetera, Elisa Pesce, Serena Uccello, Stefania Villa, Tiziana Montemurro, Larysa Mykhailova, Camilla E M Merli, Ermelinda Monti, et al.

    Although topical corticosteroids (TCS) represent first-line treatment for vulvar lichen sclerosus (VLS) and as such should be prescribed to all women at time of diagnosis, approximately 30% of patients do not experience complete symptom resolution following such treatment. TCS may not effectively improve vulvar trophism and elasticity, both of which are crucial for sexual function. Owing to its regenerative and healing properties, cord blood platelet-rich plasma (CB-PRP) may represent an efficacious supplementary therapy, to be administered following first line treatment with TCS. The primary aim of this study was to assess safety and tolerability of CB-PRP in women with VLS. This is a pilot study which precedes a randomized controlled trial of CB-PRP vs placebo in women with VLS. Ten consecutive patients with VLS, who had previously undergone standard TCS-treatment, received three vulvar CB-PRP injections monthly. Follow-up was conducted three months after the last injection using vulvoscopy and validated questionnaires to evaluate safety and tolerability, as well as patient satisfaction, symptom improvement, sexual function, psychological well-being, quality of life, frequency of TCS application as a maintenance treatment, vulvar trophism and architectural modifications. No adverse clinical effects were observed. Five patients (50%) were either satisfied or very satisfied with the procedure, four (40%) were uncertain about their satisfaction with the treatment. One patient (10%) dropped out for personal reasons and was classified as unsatisfied according to an intention-to-treat analysis. At follow-up median numeric rating scale scores were significantly reduced for vulvar burning compared to baseline (p<0.05) there was a trend toward improvement in itching, dyspareunia, and dysuria. A significant improvement in sexual arousal and satisfaction was observed in all treated women (p<0.05). CB-PRP may be a promising treatment for VLS. It appears to be safe and improve symptoms and sexual function.


  • Multi-component cord blood banking: a proof-of-concept international exercise

    by Dinara Samarkanova, Margarita Codinach, Tiziana Montemurro, Larysa Mykhailova, Giuseppa Tancredi, Pasquale Gallerano, Panagiotis Mallis, Efstathios Michalopoulos, Liam Wynn, Javier Calvo, et al.

    Most public cord blood (CB) banks currently discard more than 80% of umbilical CB units not suitable for hemopoietic stem cell transplant due to low stem cell count. Although CB platelets, plasma, and red blood cells have been used for experimental allogeneic applications in wound healing, corneal ulcer treatment, and neonatal transfusion, no standard procedures for their preparation have been defined internationally. A network of 12 public CB banks in Spain, Italy, Greece, the UK, and Singapore developed a protocol to validate a procedure for the routine production of CB platelet concentrate (CB-PC), CB platelet-poor plasma (CB-PPP), and CB leukoreduced red blood cells (CB-LR-RBC) using locally available equipment and the commercial BioNest ABC and EF medical devices. CB units with >50 mL volume (excluding anticoagulant) and ≥150×109/L platelets were double centrifuged to obtain CB-PC, CB-PPP, and CB-RBC. The CB-RBC were diluted with saline-adenine-glucose-mannitol (SAGM), leukoreduced by filtration, stored at 2–6°C, and tested for hemolysis and potassium (K+) release over 15 days, with gamma irradiation performed on day 14. A set of acceptance criteria was pre-defined. This was for CB-PC: volume ≥5 mL and platelet count 800–1,200×109/L; for CB-PPP: platelet count 9/L; and for CB-LR-RBC: volume ≥20 mL, hematocrit 55–65%, residual leukocytes 6/unit, and hemolysis ≤0.8%. Eight CB banks completed the validation exercise. Compliance with acceptance criteria was 99% for minimum volume and 86.1% for platelet count in CB-PC, and 90% for platelet count in CB-PPP. Compliance in CB-LR-RBC was 85.7% for minimum volume, 98.9% for residual leukocytes, and 90% for hematocrit. Compliance for hemolysis ≤0.8% decreased from 89.0 to 63.2% from day 0 to 15. K+ release increased from 3.0±1.8 to 25.0±7.0 mmol/L from day 0 to 15, respectively. The MultiCord12 protocol was a useful tool to develop preliminary standardization of CB-PC, CB-PPP, and CB-LR-RBC.